Matinas BioPharma Hlds

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The firm's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers a broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Matinas BioPharma advances MAT2203, faces financial challenges, and extends cash runway

Matinas BioPharma's progress on MAT2203 and positive feedback position the company well in the infectious disease treatment market.
Financially, the company faces challenges with no revenue, high expenses, and a need to carefully manage cash reserves for sustained operations.
Opportunities lie in advancing MAT2203 towards Phase III trials, exploring new therapeutic areas, and extending cash runway for future growth.
Overall, Matinas BioPharma's focus on innovation and strategic partnerships sets the stage for potential growth and market leadership in infectious disease treatments.

Matinas BioPharma reports improved Q2 performance and advances key drug programs

Matinas BioPharma's Q2 2024 performance reflects improved cost management and financial stability, supported by a strengthened cash position and ongoing progress in key drug development programs.
While challenges persist in revenue generation and trial timelines, the company's strategic strengths in product pipeline expansion and innovation present opportunities for future growth and market success.
Overall, Matinas BioPharma's focus on advancing key drug candidates and addressing clinical needs in fungal infections positions the company for potential revenue growth and market leadership in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 –

Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial –

Matinas BioPharma Provides Business Update and 2022 Strategic Outlook

Conference call and live audio webcast scheduled for Tuesday, January 25th at 8:30 a.m. ET Conference call and live audio webcast scheduled for Tuesday, January 25th at 8:30 a.m. ET

Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022

– DSMB evaluated both safety and efficacy data in recommending cohort progression –

Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

Agile Therapeutics

Gran Tierra Energy

Palatin Technologies

Looking for cheap penny stocks to buy? Here are 4 to watch trading below $1 right now.

Penny Stocks To Buy For Under $1 & What To Watch Right Now

BEDMINSTER, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the appointment of Thomas Hoover to the newly created position of Chief Business Officer.

Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer

BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, has been invited to present a Company overview at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29 – December 2, 2021. The Company will also host investor meetings during the conference.

Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference

Phunware Inc

Progenity

Verb Technology Company Inc

Xeris Biopharma Holdings

Penny stocks to buy right now according to analysts. The post 5 Penny Stocks To Buy According To Analysts With Targets Up To 156% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Analysts With Targets Up To 156%

Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerome Jabbour on Q3 2021 Results - Earnings Call Transcript

– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recommended progression to second half of study –

Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights

Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

BEDMINSTER, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced that Matinas BioPharma has been selected for inclusion in the B. Riley Fall 2021 Growth Biotech Best Ideas Series. As part of the series, Jerome D. Jabbour, Chief Executive Officer of Matinas, and other members of the Matinas leadership team will participate in a fireside chat on Tuesday, November 23, 2021.

Matinas BioPharma Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best Ideas Series

– Phase 1 study of oral amikacin in healthy volunteers expected to complete in Q1 2022 – – Phase 1 study of oral amikacin in healthy volunteers expected to complete in Q1 2022 –

Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501

Matinas Biopharma Holdings, Inc. (MTNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Matinas Biopharma Holdings, Inc. (MTNB) Upgraded to Buy: Here's What You Should Know

Senmiao Technology

BEST Inc - ADR

TransCode Therapeutics

ReWalk Robotics

These penny stocks exploded during today's trading session, are they worth watching or not? The post 5 Penny Stocks to Watch That Exploded Today, What You Need to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks to Watch That Exploded Today, What You Need to Know

– Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly –

Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors

The stock price of Matinas BioPharma Holdings Inc (NYSEAMERICAN: MTNB) increased over 10% during intraday trading today. These are the details.

MTNB Stock: The Momentum Continues Today

BEDMINSTER, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, presented a Company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Investment Conference

The stock price of Matinas BioPharma Holdings Inc (NYSEAMERICAN: MTNB) increased by over 7% pre-market today. This is why it happened.

MTNB Stock: Why It Increased Today

Matinas BioPharma Holdings Inc (NYSE: MTNB) has announced positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).

Matinas BioPharma Stock Jumps After Meningitis Candidate Data

– Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.20 –

Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold

Method-of-use patent strengthens and diversifies MAT2203's long-term patent portfolio Method-of-use patent strengthens and diversifies MAT2203's long-term patent portfolio

Matinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour on Q2 2021 Results - Earnings Call Transcript

– Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from second cohort anticipated September 2021 –

Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights

BEDMINSTER, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat as part of the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m. ET. The Company will also host investor meetings during the conference.

News for Matinas BioPharma Hlds Stock (MTNB)